摘要:
The present invention provides a compound of the general formula (I) or a pharmaceutical salt thereof, 1 wherein, when R1 and R2 are the same they are represented by nullO, nullN, nullOR9 (where R9 is hydrogen, lower alkyl or benzyl), when R1 and R2 are different and one of R1 and R2 is represented by hydrogen, the other is represented by nullR5nullR6null, (where R5 is nullOnull, nullNHnull, nullNHCOnull, or nullNHSO2null, and where R6 is hydrogen, lower alkyl, nullPhnullR7, null(CH2)nnullOnullPhnullR7, (where nnull1-6, R7 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or pyridyloxy), indolyl, N-oxidepyridyl, phthalimide, thienyl, or pyridyl); R3 represents nullCOOH, nullCOOEt, nullCOOMe, nullCH2N(OH)CHO, or nullCONHOH; R4 represents lower alkyl, thienyl, nullPhnullR8 (where R9 represents hydroxy, lower alkyl, lower alkoxy, nitro, halogen, pyridyloxy, or phenyl group substituted hydrogen, lower alkyl, lower alkoxy, hydroxy, and halogen), and methods of making compounds within the class of the general formula (I).
摘要:
Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof wherein:R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 are the same or different and represent hydrogen, halogen, alkyl, alkoxy, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy; --O.sub.2 CR', --NHCOR', --COR', --SO.sub.m R', where R' is C.sub.1 -C.sub.6 alkyl and wherein m is 0, 1 or 2; orR.sub.1 R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.8 is hydrogen or lower alkyl;X represents an optionally substituted alkylene group; andY represents a mono-, di- or trisubsituted cyclic amino group,which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.
摘要:
The invention concerns novel phosphanoxides of formula 1 in which R.sup.1 means aryl or heteroaryl group. The invention further concern the optically active forms, racemates and diastereomers mixtures of these compounds, a method of preparing them and pharmaceutical compositions containing these compounds, and methods of use to produce a thrombin-inhibiting effect.
摘要:
The invention concerns novel anabaseine-related compounds that are useful in treating certain degenerative neural diseases such as Alzheimer's and Parkinson's which apparently involve decreased function of cerebral cortical nicotinic receptors. The compounds showed activity in both in vitro and in active and passive active avoidance studies in animal models. An exemplary active compound is a 3-substituted 2,4-dimethoxy-benzylidene anabaseine.
摘要:
2-Chloromethyl-3-(tri-O-benzyl-.alpha.-L-C-fucopyranoside)-1-propene and methods of making the same are described. Methods of combining this substituted fucopyranose with triterpenoid acid also are described.
摘要:
Polyalkylpiperidine-containing acetic acid and 3-aminoacrylic acid derivatives I ##STR1## where R.sup.1 is hydrogen, C.sub.1 - to C.sub.6 -alkyl, formyl, C.sub.2 - to C.sub.6 -alkanoyl, C.sub.1 - to C.sub.12 -alkoxy, C.sub.5 - to C.sub.6 -cycloalkoxy, cyanomethyl, hydroxymethyl, 2-hydroxyethyl or a radical of the formula --CR.sup.3 =CH--CO--OR.sup.4, whereR.sup.3 is hydrogen, C.sub.1 -to C.sub.6 -alkyl or a radical of the formula --CO--OR.sup.4 andR.sup.4 is C.sub.1 - to C.sub.20 -alkyl, C.sub.5 - to C.sub.8 -cycloalkyl, C.sub.7 - to C.sub.18 -aralkyl, phenyl, tolyl or a radical of the formula --(CH.sub.2 CH.sub.2 O).sub.n H or --[CH(CH.sub.3)CH.sub.2 O].sub.n H, where n is a number from 1 to 30,X is O, NH or NR.sup.6, whereR.sup.6 is C.sub.1 - to C.sub.12 -alkyl, andY is hydrogen or a group of the formula =CH--NHR.sup.7 or =CH--NR.sup.6 R.sup.7, whereR.sup.7 is phenyl which can be substituted by one to three C.sub.1 - to C.sub.12 -alkyl, C.sub.1 - to C.sub.12 -alkoxy, halogen, cyano, hydroxyl, phenyl or groups of the formula --CO--OR.sup.5, --CO--R.sup.5, --CO--NHR.sup.5, --O--CO--R.sup.5 or --NH--CO--R.sup.5, is a 5- or 6-membered unsaturated or saturated heterocyclic ring having up to three hetero atoms from the group comprising nitrogen, oxygen and sulfur, which can additionally be benzo-fused and substituted by one to three C.sub.1 - to C.sub.12 -alkyl, C.sub.1 - to C.sub.12 -alkoxy, halogen, cyano, hydroxyl, phenyl, phenoxy or C.sub.1 - to C.sub.12 -alkoxycarbonyl are described.
摘要:
The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.
摘要:
A process of synthetizing an acetal, which comprises reacting,i) a compound represented by formula (I); ##STR1## withii) at least one compound selected from the group consisting of paraformaldehyde, trioxane and compound represented by formula (II); ##STR2## iii) a compound represented by formula (III); ##STR3## in the presence of at least one of a Lewis acid and a metal salt to synthesize the acetal represented by formula (IV); ##STR4## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and X.sub.1 have the same meaning as those in claim (I).